New Drugs and Clinical Trials · us
Oral weight-loss drug VK2735 enters Phase 3 trials to evaluate efficacy over 68 weeks
Viking will evaluate the weight-loss effects of a once-daily oral dual GLP-1/GIP receptor agonist in a total of 1,120 adults. As development moves from short-term weight loss toward long-term treatment, sustained efficacy and patient tolerability will be central to these trials.
For a weight-loss drug to become a long-term treatment option, the test goes beyond how much weight patients lose in the first few months. It also includes whether the effects last and whether patients can continue taking it. Viking Therapeutics announced on October 14 that its oral drug candidate VK2735 had entered the SUNRISE Phase 3 clinical program, which will use a 68-week treatment period to address these longer-term questions.
VK2735 is a dual agonist that activates both GLP-1 and GIP receptors. This development approach seeks to combine two incretin signals to improve weight and metabolic regulation. The oral formulation offers an alternative to injections, but whether its convenience translates into better long-term treatment persistence still requires clinical evidence.
According to the company announcement and a same-day report by BioPharm International, SUNRISE-1 and SUNRISE-2 each plan to enroll 560 participants, using multicenter, randomized, double-blind, placebo-controlled designs. Both trials will compare once-daily oral VK2735 at doses of 27.5, 35 or 55 milligrams with placebo. The primary assessment will be the percentage change in body weight from baseline at week 68. The trials will also calculate the proportions of participants who lose at least 5%, 10%, 15% and 20% of their body weight, providing a clearer picture of the distribution of treatment effects beyond the average.
The two studies differ in participants’ diabetes status. SUNRISE-1 will enroll adults without type 2 diabetes who have obesity, or who are overweight with at least one weight-related comorbidity; SUNRISE-2 will enroll adults with obesity or overweight who also have type 2 diabetes. Evaluating these populations separately will help clarify the drug’s efficacy and safety in different metabolic settings.
The early evidence supporting this advance comes from the Phase 2 VENTURE-Oral study, which the company reported in 2025. As reviewed in Viking’s latest announcement, mean body weight reductions across the oral VK2735 dose groups reached up to 12.2% after 13 weeks of treatment; the most common treatment-emergent adverse events were gastrointestinal symptoms. However, the highest mean reduction in a short-term study cannot be used directly to predict efficacy at 68 weeks, nor is it sufficient to establish the safety of longer-term use.
Oral and injectable formulations are also being developed in parallel. A report by S&P Capital IQ published on MarketScreener confirmed that Viking also has a maintenance treatment trial underway, while both VANQUISH Phase 3 studies of subcutaneous VK2735 have completed enrollment. These programs examine initial weight loss and subsequent weight management, respectively, but each still needs to deliver results before the practical uses of different dosing strategies can be assessed.
SUNRISE currently marks a new step into large-scale, longer-term evaluation; Phase 3 efficacy results have not yet been announced. Because the comparator is placebo, the studies also cannot directly answer whether VK2735 is superior to other weight-loss drugs. The key questions ahead are whether the degree of weight loss can be maintained, and whether long-term safety and treatment discontinuation patterns support continued treatment.